Cagrilintide: Benefits, Dosage & FDA Status
Cagrilintide (long-acting amylin analog)
A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.
FDA Status
Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress
Typical Dose
Trial range: 0.16–4.5 mg weekly (subcutaneous)
Evidence Grade
AStrong RCT or FDA-approved evidence
Half-Life
~7 days
Routes of Administration
subcutaneous
First Synthesized
2020
Clinics Indexed
8 providers have offered Cagrilintide in our tracked directory.
Mechanism of Action
Long-acting amylin receptor agonist; adds amylin-pathway satiety signaling on top of GLP-1 agonism.
Key Reported Benefits
- ✓Amylin pathway weight loss
- ✓Synergy with GLP-1
- ✓Lower-dose tolerability
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade A indicates strong rct or fda-approved evidence.
Reported Side Effects
- •Nausea
- •GI discomfort
- •Injection-site reactions
Contraindications
- ⚠Pregnancy
- ⚠Type 1 diabetes (without specialist care)
Commonly Stacked With
Regulatory & Safety Context
FDA status: Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Cagrilintide. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semaglutide
A+A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
Tirzepatide
A+A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
Liraglutide
A+The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
Retatrutide
ATriple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
Survodutide
AA dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
AOD-9604
C+A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.